AptaC – Aptamers and fusion aptamers binding haemostatic molecules for diagnostic and therapeutic use
Activated protein C (APC) plays a key role in vascular and inflammatory diseases. As endogenous inhibitor APC inactivates blood clotting factors Va and VIIIa controlling plasmatic haemostasis.
The inventions provide aptamers as diagnostic tools for detection of APC in biological samples also in the presence of abundant inactive protein C with high selective specificity. This allows establishment of routine diagnostics for APC to analyse disturbances in haemostasis, e.g. in sepsis or in haemophilia A. Further the inventions provide therapeutic aptamers binding to APC for the control of bleeding events, e.g. in haemophilia A or Willebrand syndrome.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
